Search Orphan Drug Designations and Approvals
-
Generic Name: | 3-(3-(3,5-Dimethyl-1H-pyrazol-4- yl)propoxy)-4-fluorobenzoic acid |
---|---|
Date Designated: | 10/02/2018 |
Orphan Designation: | Treatment of transthyretin amyloidosis |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
BridgeBio Pharma, Inc. 3160 Porter Drive Palo Alto, California 94301 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-